Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-β, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)

Hepatology

Volumn 33, Issue 1, 2001, Pages 254-266

  Peek, Simon F ^a   Cote, Paul J ^b   Jacob, James R ^a   Toshkov, Ilia A ^a   Hornbuckle, William E ^a   Baldwin, Betty H ^a   Wells, Frances V ^b   Chu, C K ^c   Gerin, John L ^b   Tennant, Bud C ^a   Korba, Brent E ^b  

^a Department of Population Medicine and Diagnostic Sciences   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEVUDINE; CORE PROTEIN; VIRUS DNA; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DUCK; FEMALE; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATITIS VIRUS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REBOUND; SCIURIDAE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; WOODCHUCK;

EID: 0035196639     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.20899     Document Type: Article

References (54)

1. Inhibitory effect of 2-fluoro-5-methyl-beta-L-arabino-furanosyl-uracil on duck hepatitis B virus replication
2. Inhibition of hepatitis B virus by a novel L-nucleoside, 2-fluoro-5-methyl-beta-L-arabinofuranosyl uracil
3. Use of 2-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus
4. Sensitivity of L-(-)2, 3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
5. Structure-activity relationships of 2′-deoxy-2′, 2′-difluoro-L-erythro-pento-furanosyl nucleosides
6. Unique inhibitory effect of 1-(2′-deoxy-2′-fluoro-β-L-arabinofuranosyl)-5-methyluracil 5′-triphosphate on Epstein-Barr virus and human DNA polymerases
7. Synthesis and antihepatitis B virus activity of 9-(2-deoxy-2-fluoro-β-L-arabinofuranosyl) purine nucleosides
8. Structure-activity relationships of 1-(2-deoxy-2-fluoro-β, L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents
9. 19F NMR study of the uptake of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil in erythrocytes: Evidence of transport by facilitated and nonfacilitated pathways
10. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-ambinofuranosyluracil
11. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection
12. Pharmacokinetics of 1-(2-fluoro-5-methyl-β, L-arabinofuranosyl)uracil in woodchucks
13. Histopathologic changes associated with fialuridine hepatotoxicity
14. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
15. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides to woodchuck hepatitis virus replication in chronically infected woodchucks
16. Experimental WHV infection of woodchucks: An animal model of hepadnavirus-induced liver cancer
17. Influence of age on the response to experimental woodchuck hepatitis virus infection
18. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: In vitro and in vivo studies
19. No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production
20. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection
21. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramnscular route
22. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks
23. Liver-targeted antiviral nucleosides: Enhanced antiviral activity of phosphatidyldideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo
24. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: Drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles
25. Antiviral and anti-proliferative activities of α-interferon in experimental hepatitis B virus infections
26. Lamivudine therapy of WHV-infected woodchucks
27. Antiviral activity of ganciclovir, 9-(1, 3-dihydroxy-2-propoxymethyl) guanine against woodchuck hepatitis virus: Quantitative measurement of woodchuck hepatitis virus DNA using storage phosphor technology
28. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1- [2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks
29. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking
30. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
31. Viral pharmacodynamics of (-)-B-2′, 3′-dideoxy-3′-thiacytidine in chronically infected woodchucks compared to humans
32. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks
33. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically-infected woodchucks
34. Treatment of chronic WHV infection in the Eastern woodchuck (M. Monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in man
35. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic WHV carrier woodchucks
36. Antiviral activity of oral 1-O-hexadecyl-propanediol-3-P-acyclovir in woodchucks with chronic woodchuck hepatitis virus infection
37. Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-β, L-arabinofuranosyl)uracil (L-FMAU) in rats
38. Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats
39. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fiuoro-5- methyl-β, L-arabinofuranosyluracil: A substrate for both thymidine kinase and deoxycytidine kinase
40. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection
41. Hepadnavirus infection of peripheral blood lymphocytes in vivo: Woodchuck and chimpanzee models of viral hepatitis
42. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: Presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections
43. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection
44. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus
45. Hepatic expression of the woodchuck hepatitis X-antigen during acute and chronic infection and detection of a woodchuck hepatitis virus X-antigen antibody response
46. Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: Increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection
47. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway
48. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
49. Replication of the genome of a hepatitis-B-like virus by reverse transcription of an RNA intermediate
50. Hepadnaviridae: The viruses and their replication
51. Lamivudine. A review of its therapeutic potential in chronic hepatitis B
52. Hepatitis B virus biology
53. Viral dynamics in hepatitis B virus infection
54. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy